<qa>  To determine the toxicities and ability to complete the planned treatment of a dose-denseI. To determine the toxicities and ability to complete the planned treatment of a dose-dense regimen of cyclophosphamide and paclitaxel with trastuzumab in subjects with newly diagnosed stage I-II HER2neu positive breast cancer. 